
ABOUT DIA
For more than 50 years, DIA (the Drug Information Association), a non-profit association, has served as a global forum for all those involved in healthcare product development and lifecycle management to exchange knowledge and collaborate in a neutral setting. DIA is an essential resource that provides opportunities to extend debate and discussion to advance scientific and medical innovation. DIA fosters innovation to improve health and well-being worldwide by: Providing invaluable forums to exchange vital information and discuss current issues related to healthcare products, technologies, and services; Delivering customized learning experiences; Building, maintaining, and facilitating trusted relationships with and among individuals and organizations that drive and share DIA values and mandates; and offering a multidisciplinary neutral environment, respected globally for integrity and relevancy. DIA is your essential partner in catalyzing knowledge creation and sharing to accelerate healthcare product development.
FEATURED ARTICLES
-
An innovative educational outreach initiative has hit the road to spread awareness about clinical research and highlights the importance of diverse representation in clinical trials.
-
Explore a proposed digital ecosystem that would balance rigorous validation with the urgent need for accessible mental health solutions, transforming the landscape into a reliable resource for global well-being.
-
Delve into the transformative role and potential benefits of Artificial Intelligence (AI) in healthcare and learn why it's crucial to carefully consider and plan for the responsible use of AI.
-
Explore how the partnerships between cutaneous T-cell lymphoma (CTCL) patients, physicians, and researchers is leading to advancements in diagnosing and managing this life-threatening disease.
-
As Pharmacovigilance (PV) evolves into a proactive, value-driven discipline innovations like robotic process automation and artificial intelligence help improve efficiency and data utility.
-
As regulators adapt to new challenges, including pandemics and the rise of advanced therapies, their commitment to innovation, collaboration, and patient safety remains paramount, shaping the future of global health.
-
By focusing on updating regulatory frameworks, developing technical standards, and leveraging technology for compliance, see how the industry can ensure that digital and remote trials are conducted safely and ethically.
-
Discover how global stakeholders are working together to streamline regulatory processes and enhance transparency through reliance approaches in post-approval changes (PACs).
-
Discover the human stories behind the halted clinical trials in Ukraine and understand the broader impact on medical research and patient care.
-
Review the current and future applications of RWD/E in drug discovery, clinical research, regulatory review and approval, and its role in promoting health equity and patient and provider access.
-
Following the simple logical flow we recommend for all Global Forum articles—What, So What, Now What—let’s delve into why DIA remains a cornerstone for professional growth and innovation in our field.
-
Begin your journey to AI-driven clinical research by capturing high-quality electronic data, paving the way for transformative operations, deeper insights, and smarter protocols.
-
Gain insight into the critical importance of proactive engagement, collaborative partnerships, and continuous education to navigate these challenges effectively.
-
By elucidating the barriers impeding progress on the PPI adoption curve and offering actionable insights, this article aims to catalyze renewed efforts toward harnessing the full potential of patient engagement in shaping the future of healthcare delivery.
-
Listen to former DIA Board President Minnie Baylor-Henry’s special message to DIA members as part of DIA’s 60th Anniversary celebration in 2024.
-
This exploration not only illuminates the remarkable strides made in combating cancer but also underscores the pivotal role of cutting-edge technologies in shaping the trajectory of oncological care.
-
By embracing its foundational pillars, learn how DIA continues to address ongoing challenges in drug information and healthcare as it enters its seventh decade in the industry.
-
By fostering daily interactions between patients and technology, these smart hubs offer a sustainable approach to ensuring the success and integrity of clinical trials in an evolving landscape of drug development.
-
With over 180 sessions across 13 tracks and nine engaging learning formats, attendees will delve into emerging fields such as precision medicine, regulatory CMC, and product quality, and value-based access.
-
Gain insight from several industry experts on how real-world data can be used to advance clinical research and enhance the landscape of therapeutic product development.
-
To ensure technological innovations make a tangible impact in the real world, discover why it is imperative to cultivate an environment that is both receptive and prepared to embrace and integrate them.
-
Explore how the combination of tech innovations and the human touch could seamlessly align advancements in clinical research with the diverse needs of participants and caregivers.
-
Learn how this collaborative approach ensures better patient experiences without overwhelming sites or diverting their focus from participants.
-
Learn why adopting AI-driven risk-based quality management will be essential in ensuring the accuracy of data from diverse sources.
-
Get a comprehensive examination of the impact of a lack of diversity in public health, delving into the various barriers that historically marginalized populations encounter when attempting to participate in clinical research.
-
Examine the various routes for expediting drug development and approval in member countries of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, as well as in Australia.
-
Delve into a collection of select case studies where various examples of RWD/RWE applications are analyzed for strengths and weaknesses as perceived by regulatory agencies, illustrating key insights with regard to study design.
-
Gain insight from several tactics that could arguably contribute to enhancing the diversity and inclusivity of studies throughout the entire clinical trial process.
-
Recent FDA and EMA guidance highlight the importance of human involvement when using technology in clinical trials.
-
Consider DIA GCP & QA Community Chair Terry Katz’s perspective on repurposing and analyzing EHR data for clinical research.
-
Gain insight from five take-home messages highlighting practical approaches to mitigate risks and providing incentives for utilizing patient-generated data.
-
Learn about what the industry considers RWD/RWE priorities for the year, as well as current efforts being taken within each region around the globe.
-
Learn about ethical research practices and how the approved uses of AI technology in the life sciences industry must be developed within a regulatory framework to ensure its meaningful and standardized utility.
-
Consider the ways in which generative AI can enhance the productivity of skilled professionals like medical writers, bridge skill gaps, facilitate resource upskilling, transform data into actionable intelligence, and provide valuable insights.
CONTACT INFORMATION
DIA
800 Enterprise Road, Suite 200
Horsham, PA 19044-3595
UNITED STATES
Phone: 215.442.6100
Fax: 215.442.6199
Contact: Michelle Rovner
VIDEOS AND PODCASTS
-
While patient enrollment remains a challenge in clinical trials, new emerging technologies are working to improve accessibility and serve as a viable solution.
-
Delve into the transformative concept of “turning barriers into bridges” to cultivate a diverse and well-prepared clinical research workforce.